Northwell Health
Northwell Health - Hofstra Zucker School of Medicine
New York, New York, United States
Dr. Art Rastinehad, D.O. initially joined the faculty at Northwell Health in 2011. Most recently, he was named Northwell Health’s System Director for Prostate Cancer at the Cancer Institute and the Vice Chair at the Smith Institute for Urology at Lenox Hill Hospital (January 2020). He has expertise in a wide array of interventional radiological and surgical techniques, including image guided procedures, prostate artery embolization, laparoscopic and robotic surgery.
Dr. Rastinehad has also authored and implemented several clinical trials of new techniques in the diagnosis and treatment of localized prostate cancer. In 2011 at Northwell Heath, he was the principal investigator for a Phase III clinical trial using MRI/Ultrasound fusion technology to improve prostate biopsy techniques and validated the original work from the NIH’s UOB/MIP/CIO programs. This was the first trial of this technology in the United States outside the National Institutes of Health. Dr. Rastinehad is considered one of the pioneers of this field, bringing prostate MRI and MR/US fusion guided prostate biopsy from the bench to clinical practice.
This new clinical approach is the groundwork for the evaluation of a new technique, Focal Therapy, which treats only the diseased portion of the prostate. While at the NIH, Dr. Rastinehad designed and authored the first trial assessing the utility of MR guided focal ablation of prostate tumors using MR US fusion biopsy data with Dr. Pinto as the PI (2010). As of May 2016, Dr Rastinehad was the first in the world to perform a gold nanoparticle directed ablation using a transperineal MR/US Fusion guided focal therapy system.
Dr Rastinehad is also one of the founding executive board members of the Focal Therapy Society, which was started in October 2019 in collaboration with the Endourological Society.
Disclosure information not submitted.